Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

Description

The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).

Conditions

Borderline Personality Disorder, Major Depressive Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).

An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

Condition
Borderline Personality Disorder
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Chicago, Chicago, Illinois, United States, 60637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18-65
  • * Diagnosed with current major depressive disorder
  • * Montgomery-Asberg Depression Rating Scale (MADRS) score of \> 20
  • * Diagnosed with borderline personality disorder
  • * Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) score of \> 20
  • * Ability to understand and sign the consent form
  • * Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
  • * Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
  • * Illegal substance use based on urine toxicology screening (except cannabis use)
  • * Current or past history of bipolar I disorder, schizophrenia, or schizoaffective disorder
  • * Active substance use disorder

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Chicago,

Jon E Grant, MD, JD, MPH, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

2025-07